SG Sides Against Novo In Dispute Over Generics

Law360, New York (May 26, 2011, 8:30 PM EDT) -- The U.S. solicitor general said Thursday that the U.S. Supreme Court should overturn a ruling in a suit between Caraco Pharmaceutical Laboratories Ltd. and Novo Nordisk A/S that makes it easier for name-brand drugmakers to avoid generic competition.

U.S. Acting Solicitor General Neal Kumar Katyal said that a 2010 Federal Circuit ruling lets brand-name drugmakers file misleading descriptions of their patents in the U.S. Food and Drug Administration's so-called Orange Book — case law that could ultimately stop billions of dollars in legitimate generic drugs from...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.